Quinolines and pharmaceutical compositions thereof
申请人:Wyeth
公开号:US07576215B2
公开(公告)日:2009-08-18
This invention provides compounds of formula I
that are useful in the treatment or inhibition of LXR mediated diseases.
本发明提供了I式化合物,可用于治疗或抑制LXR介导的疾病。
4-(3-Aryloxyaryl)quinoline alcohols are liver X receptor agonists
作者:Ronald C. Bernotas、David H. Kaufman、Robert R. Singhaus、John Ullrich、Rayomand Unwalla、Elaine Quinet、Ponnal Nambi、Anna Wilhelmsson、Annika Goos-Nilsson、Jay Wrobel
DOI:10.1016/j.bmc.2009.10.001
日期:2009.12
A series of 4-(3-aryloxyaryl)quinolines with alcohol substituents on the terminal aryl ring was prepared as potential LXR agonists, in which an alcohol group replaced an amide in previously reported amide analogs. High affinity LXR ligands with excellent agonist potency and efficacy in a functional model of LXR activity were identified, demonstrating that alcohols can substitute for amides while retaining LXR activity. The most potent compound was 5b which had an IC50 = 3.3 nM for LXR beta binding and EC50 = 12 nM (122% efficacy relative to T0901317) in an ABCA1 mRNA induction assay in J774 mouse cells. (C) 2009 Elsevier Ltd. All rights reserved.
QUINOLINES USEFUL IN TREATING CARDIOVASCULAR DISEASE